Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer.
Data from two Phase III studies showed at ESMO that patients with BRCA1/2 mutations and HRD are living longer with maintenance therapy with Lynparza alone and in combination with Avastin.
Landmark 5-year follow-up of PAOLA-1 Phase III trial demonstrated LYNPARZA plus bevacizumab meaningfully extended survival with 65.5% of HRD-positive patients surviving 5 years vs. 48.4% treated with
Lynparza in combination with bevacizumab, and as monotherapy, demonstrates clinically meaningful survival benefit miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.